Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope

被引:20
|
作者
Ciernik, IF
Romero, P
Berzofsky, JA
Carbone, DP
机构
[1] CHU Vaudois, Lausanne Branch, Ludwig Inst Canc Res, Div Clin Oncoimmunol, CH-1011 Lausanne, Switzerland
[2] NCI, Metab Branch, Bethesda, MD 20892 USA
[3] Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, Nashville, TN USA
关键词
mutant p53; T-cell epitopes; tumor vaccine; cellular immunity; radiation; tumor immunogenicity;
D O I
10.1016/S0360-3016(99)00226-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: p53 point mutations represent potential tumor-specific cytolytic T lymphocyte (CTL) epitopes. Whether ionizing radiation (IR) alters the immunological properties of cells expressing mutant p53 in respect of the CTL epitope generated by a defined point mutation has not been evaluated. Methods: Mutant p53-expressing syngeneic, nontumor forming BALB/c 3T3 fibroblasts, tumor forming ras-transfected BALB/c 3T3 sarcomas, and DBA/2-derived P815 mastocytoma cells, which differ at the level of minor histocompatibility antigens, were used as cellular vaccines. Cells were either injected with or without prior IR into naive BALB/c mice. Cellular cytotoxicity was assessed after secondary restimulation of effector spleen cells in vitro. Results: Injection of P815 mastocytoma cells expressing the mutant p53 induced mutation-specific CTL in BALB/c mice irrespective of prior irradiation. However, syngeneic fibroblasts or fibrosarcomas endogenously expressing mutant p53 were able to induce significant mutation-specific CTL only when irradiated prior to injection into BALB/c mice. IR of fibroblasts did not detectably alter the expression of cell surface molecules involved in immune response induction, nor did it alter the short-term in vitro viability of the fibroblasts. Interestingly, radioactively-labeled fibroblasts injected into mice after irradiation showed altered organ distribution, suggesting that the in vivo fate of these cells may play a crucial role in their immunogenicity. Conclusions: These findings indicate that IR can alter the immunogenicity of syngeneic normal as well as tumor forming fibroblasts in vivo, and support the view that ionizing radiation enhances immunogenicity of cellular tumor vaccines. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:735 / 741
页数:7
相关论文
共 50 条
  • [21] Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cells
    Cheol-Hun Son
    Hong-Rae Lee
    Eun-Kyoung Koh
    Dong-Yeok Shin
    Jae-Ho Bae
    Kwangmo Yang
    You-Soo Park
    Scientific Reports, 6
  • [22] Transcriptional analysis of tumor-specific T-cell responses in cancer patients
    Nagorsen, D
    Wang, E
    Marincola, FM
    Even, J
    CRITICAL REVIEWS IN IMMUNOLOGY, 2002, 22 (5-6) : 449 - 462
  • [23] In situ detection of virus- and tumor-specific T-cell immunity
    Haanen, JBAG
    Van Oijen, MGCT
    Tirion, F
    Oomen, LCJM
    Kruisbeek, AM
    Vyth-Dreese, FA
    Schumacher, TNM
    NATURE MEDICINE, 2000, 6 (09) : 1056 - 1060
  • [24] In situ detection of virus- and tumor-specific T-cell immunity
    John B.A.G. Haanen
    Monique G.C.T. van Oijen
    Felicia Tirion
    Lauran C.J.M. Oomen
    Ada M. Kruisbeek
    Florry A. Vyth-Dreese
    Ton N.M. Schumacher
    Nature Medicine, 2000, 6 : 1056 - 1060
  • [25] Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma
    Woods, Katherine
    Cebon, Jonathan
    CLINICAL CANCER RESEARCH, 2013, 19 (15) : 4021 - 4023
  • [26] Rescuing tumor-specific T cells from cell death
    Davila, Eduardo
    Geng, Degui
    Sanchez-Perez, Luis
    Riker, Adam
    IMMUNOTHERAPY, 2009, 1 (06) : 921 - 922
  • [27] SINGLE-CHAIN T-CELL RECEPTOR AS A TUMOR-SPECIFIC VACCINE
    WONG, CP
    OKADA, CY
    LEVY, R
    FASEB JOURNAL, 1995, 9 (03): : A514 - A514
  • [28] TUMOR-SPECIFIC T-CELL IMMUNITY - READY FOR PRIME-TIME
    GREENBERG, PD
    RIDDELL, SR
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (14): : 1059 - 1061
  • [29] Therapeutic vaccine strategies to induce tumor-specific T-cell responses
    Ana Marcu
    Matthias Eyrich
    Bone Marrow Transplantation, 2019, 54 : 806 - 809
  • [30] Tumor-specific delivery of biologics by a novel T-cell line HOZOT
    Onishi, Teppei
    Tazawa, Hiroshi
    Hashimoto, Yuuri
    Takeuchi, Makoto
    Otani, Takeshi
    Nakamura, Shuji
    Sakurai, Fuminori
    Mizuguchi, Hiroyuki
    Kishimoto, Hiroyuki
    Umeda, Yuzo
    Shirakawa, Yasuhiro
    Urata, Yasuo
    Kagawa, Shunsuke
    Fujiwara, Toshiyoshi
    SCIENTIFIC REPORTS, 2016, 6